Evaluation of NT PRO BNP Guided Therapy on Hospitalization Rate and Mortality in Patients With Chronic HF NYHA II-IY
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To use continuous measurement of NT Pro BNP level as guide in therapy patients with CHF.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Heart Failure |
Procedure: Treatment according NT Pro BNP level |
Phase 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Phase 1 Study of Using BNP as Guided Parameter in Treatment HF |
| Enrollment: | 108 |
| Study Start Date: | June 2007 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Group of 100 patients with CHF, NYHA II-IY will be followed for 1 years in outpatient clinic of our hospital for hospitalization, death, 6 min walking protocol, number of decompensation as a primary end point. 50 patients will be treated according usual practice in outpatient clinics and in 50 patients will be additionally used level of NT Pro BNP as additional parameter.If level NT Pro BNP will be goes down will not be changes in treatment regiment. If level of NT Pro BNP will be increased treatment will be intensified.At the end of 1 year follow up we will compare the result of two strategies.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with chronic heart failure. Half of the patients were treated by common medical practice for patients with heart failure. The other half were treated according to BNP values and common medical practice.
Inclusion Criteria:
- Patient older 18 y.old with CHF NYHA II-IY.
Exclusion Criteria:
- All conditions with life expectancy less than 2 years.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00469001 History of Changes |
| Other Study ID Numbers: | 00001 |
| Study First Received: | May 2, 2007 |
| Last Updated: | September 12, 2010 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Hillel Yaffe Medical Center:
|
Hospitalization and death from exacerbation CHF. |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013